Glaucoma Therapeutics

Glaucoma Therapeutics


Global Glaucoma Therapeutics Market to Reach US$7.2 Billion by 2030

The global market for Glaucoma Therapeutics estimated at US$5.7 Billion in the year 2023, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Combination Drugs segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 5.5% CAGR

The Glaucoma Therapeutics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 5.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Glaucoma Therapeutics Market - Key Trends & Drivers Summarized

How Is Aging Population Impacting the Demand for Glaucoma Treatments?

The global glaucoma therapeutics market is seeing a steady rise in demand, primarily driven by the growing elderly population. Glaucoma, a leading cause of irreversible blindness, disproportionately affects older adults, making age a significant risk factor. As life expectancy increases, particularly in developed countries, the prevalence of glaucoma has risen, intensifying the need for effective treatments. This demographic trend has prompted both governments and healthcare systems to prioritize early diagnosis and management, leading to a surge in demand for therapeutic options that can manage intraocular pressure and slow disease progression. Consequently, pharmaceutical companies are focused on developing new medications and combination therapies that can effectively serve this expanding patient base.

Why Are Innovations in Drug Delivery Systems Crucial for Glaucoma Management?

Advancements in drug delivery systems are transforming glaucoma treatment by improving the efficacy, safety, and convenience of therapeutic options. Traditional eye drops, while effective, often pose adherence challenges due to the need for frequent application, leading to inconsistent patient compliance. In response, the industry has introduced innovative delivery methods such as sustained-release implants, microdosing technologies, and minimally invasive surgical devices. These systems offer more consistent drug delivery, reducing the frequency of applications and improving overall treatment adherence. Sustained-release implants, in particular, are gaining popularity as they provide extended drug release, minimizing the need for daily eye drops and enhancing the patient experience.

How Is Increased Awareness Boosting Glaucoma Therapeutics Market?

Growing awareness about glaucoma’s severe impact on vision has led to early detection efforts and higher diagnosis rates, further driving demand for therapeutic solutions. Public health campaigns and initiatives led by governmental and non-governmental organizations aim to educate people on the importance of routine eye check-ups, especially for at-risk groups like the elderly. This proactive approach is prompting patients to seek treatment earlier, which is crucial for conditions like glaucoma, where early intervention can prevent or delay progression. Additionally, ophthalmologists are increasingly adopting advanced diagnostic tools that detect glaucoma at earlier stages, creating demand for therapeutic solutions that can effectively manage the condition from the outset.

What Drives the Growth of the Glaucoma Therapeutics Market?

The growth in the glaucoma therapeutics market is driven by several factors, including the aging population, innovative drug delivery methods, and heightened awareness about early detection. The increasing prevalence of glaucoma in elderly populations has led to sustained demand for treatment options. Innovations in drug delivery, such as sustained-release implants and microdosing technologies, are enhancing patient adherence and treatment effectiveness, making these options highly appealing. Furthermore, public health campaigns and improvements in diagnostic technology have facilitated early detection, allowing patients to start treatment sooner and improving outcomes. These drivers collectively position the glaucoma therapeutics market for continued growth as it adapts to the needs of a growing and aging patient base.

SCOPE OF STUDY:

The report analyzes the Glaucoma Therapeutics market in terms of US$ Million by the following Distribution Channel; Drug Class, and Geographic Regions/Countries:

Segments:
Drug Class (Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -
  • Aerie Pharmaceuticals, Inc.
  • Allergan, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Valeant Pharmaceuticals International, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Glaucoma Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Glaucoma and Related Eye Disorders
Growth in Geriatric Population Driving Treatment Demand
Advancements in Glaucoma Treatment Delivery Mechanisms
Increasing Availability of Minimally Invasive Glaucoma Surgeries
Expansion of Targeted Therapies for Progressive Glaucoma
Growth in Telemedicine and Online Consultations for Eye Care
Higher Demand for Combination Therapies in Glaucoma Treatment
Investment in R&D for Novel Glaucoma Medications
Rising Awareness Campaigns Boosting Early Diagnosis Rates
Development of Drug-Eluting Implants for Sustained Treatment
Increase in Accessibility of Glaucoma Therapies in Emerging Markets
Growth in Specialty Eye Clinics Enhancing Treatment Reach
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Glaucoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Glaucoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Prostaglandins Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Prostaglandins Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Prostaglandins Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Alpha Adrenergic Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Alpha Adrenergic Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Alpha Adrenergic Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Carbonic Anhydrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Carbonic Anhydrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Carbonic Anhydrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Online by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: USA Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: USA 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
CANADA
TABLE 38: Canada Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 41: Canada Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Canada 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
JAPAN
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 44: Japan Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 47: Japan Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Japan 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
CHINA
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 50: China Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 53: China Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: China Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: China 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
EUROPE
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 56: Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Glaucoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Europe Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Europe 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
FRANCE
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 65: France Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 68: France Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: France Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: France 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
GERMANY
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 71: Germany Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 74: Germany Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Germany Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Germany 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
ITALY
TABLE 77: Italy Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 80: Italy Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Italy Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Italy 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
UNITED KINGDOM
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 83: UK Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 86: UK Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: UK Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: UK 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
SPAIN
TABLE 89: Spain Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 92: Spain Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Spain Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Spain 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
RUSSIA
TABLE 95: Russia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 98: Russia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Russia Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Russia 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Rest of Europe Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Rest of Europe 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Glaucoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Asia-Pacific Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
AUSTRALIA
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 116: Australia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 119: Australia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Australia Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Australia 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
INDIA
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 122: India Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 125: India Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: India Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: India 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 128: South Korea Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 131: South Korea Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: South Korea Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: South Korea 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of Asia-Pacific Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
LATIN AMERICA
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 140: Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Glaucoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 146: Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Latin America Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Latin America 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 149: Argentina Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 152: Argentina Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Argentina Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Argentina 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
BRAZIL
TABLE 155: Brazil Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 158: Brazil Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Brazil Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Brazil 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
MEXICO
TABLE 161: Mexico Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 164: Mexico Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Mexico Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Mexico 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Rest of Latin America Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Rest of Latin America 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
MIDDLE EAST
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 173: Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Glaucoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Glaucoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 179: Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Middle East Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Middle East 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
IRAN
TABLE 182: Iran Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 185: Iran Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Iran Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Iran 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
ISRAEL
TABLE 188: Israel Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 191: Israel Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Israel Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Israel 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Saudi Arabia Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Saudi Arabia 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 200: UAE Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 203: UAE Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: UAE Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: UAE 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Rest of Middle East Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Rest of Middle East 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
AFRICA
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 212: Africa Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Glaucoma Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 215: Africa Recent Past, Current & Future Analysis for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Africa Historic Review for Glaucoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Africa 16-Year Perspective for Glaucoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings